期刊
DRUG DISCOVERY TODAY
卷 25, 期 11, 页码 1998-2005出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2020.09.016
关键词
-
资金
- Engineering and Physical Sciences Research Council (EPSRC)
- Medical Research Council (MRC) [EP/L016044/1]
Investment in phenotypic drug discovery has led to increased demand for rapid and robust target deconvolution to aid successful drug development. Although methods for target identification and mechanism of action (MoA) discovery are flourishing, they typically lead to lists of putative targets. Validating which target(s) are involved in the therapeutic mechanism of a compound poses a significant challenge, requiring direct binding, target engagement, and functional studies in relevant physiological contexts. A combination of orthogonal approaches can allow target identification beyond the proteome as well as aid prioritisation for resource-intensive target validation studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据